Skip to main content
TEVA $42.62 +0.12%
TEVA logo
TEVA · Teva Pharmaceutical Industries Ltd
Track TEVA — free
$42.62 +0.05 (+0.12%) At close · Nov 17 Play latest call Q3 2026 earnings call transcript
Market Cap
$49.73B
Shares
1.17B
Volume · Nov 17 7.02M Avg daily vol (3M) 6.16M
All webcasts

Earnings call · FY2022 Q2

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2022 Earnings Call

Concluded Jul 27, 2022
Jul 27, 2022
Period
FY2022 Q2
Runtime
—
Sources
2 artifacts
Revenue $3.79B -3.2% YoY
Diluted EPS -$0.23 -221.1% YoY
Gross margin 47.4% -0.5 pp YoY
Net income -$251.00M -221.3% YoY
Open full screen 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

Forward guidance

6 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Jul 26, 2022.

Metric Guided
Revenues
2022 outlook
$15B – $15.6B
COPAXONE revenues Lowered
2022 outlook
$700M
Adjusted EBITDA Maintained
2022 outlook
$4.7B – $5B
Non-GAAP diluted EPS Maintained
2022 outlook
$2.40 – $2.60
Free cash flow Maintained
2022 outlook
$1.9B – $2.2B
Non-GAAP tax rate
2022 outlook
13% – 14%

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

North America Segment$1.90B -2% YoY
Europe Segment$1.17B -1.1% YoY
International Markets$454.00M -6.4% YoY
Other Activities$257.00M -13.8% YoY
Full-screen source Call document